Holen Sie sich die Stockscreener-App
30.98
8.43%
-2.435
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.42
Offen:
$33
24-Stunden-Volumen:
1.51M
Relative Volume:
1.11
Marktkapitalisierung:
$1.69B
Einnahmen:
$11.13M
Nettoeinkommen (Verlust:
$-81.99M
KGV:
-17.23
EPS:
-1.7988
Netto-Cashflow:
$-68.38M
1W Leistung:
+9.68%
1M Leistung:
+36.31%
6M Leistung:
+381.17%
1J Leistung:
+139.27%
1-Tages-Spanne:
$29.41
$33.00
1-Wochen-Bereich:
$28.98
$36.49
52-Wochen-Spanne:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
31.01 | 1.82B | 11.13M | -81.99M | -68.38M | -1.7988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial Challenges - GuruFocus
Capricor Therapeutics (CAPR) Advances Duchenne Therapy with FDA Review - GuruFocus
Capricor Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Capricor (CAPR) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts - Investing.com Nigeria
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Capricor Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Capricor Looks Ahead To Deramiocel Approval In DMD - Citeline News & Insights
Capricor Therapeutics falls on Q4 earnings miss By Investing.com - Investing.com Canada
Capricor (CAPR) Focuses on Deramiocel's Approval Amid Financial Growth - GuruFocus
Capricor’s DMD therapy shows heart benefit in phase 3 trial | Tap to know more | Inshorts - Inshorts
Capricor: Q4 Earnings Snapshot - marketscreener.com
Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55 - marketscreener.com
Fourth quarter and full year 2025 earnings released, Capricor Therapeutics, Inc. outlines - Traders Union
Duchenne trial drug from Capricor slows key task decline 83% - Stock Titan
Capricor Therapeutics’ DMD treatment study shows improvement in key heart function measures - MSN
Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st
Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy - Stocktwits
Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures - Asianet Newsable
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
CAPR Stock In Focus: Capricor Says Phase 3 DMD Trial Shows Cardiac Improvement With Deramiocel - Stocktwits
Capricor earnings on deck after FDA resumes deramiocel review - Investing.com UK
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - The Manila Times
Cell therapy for Duchenne slows key eating task decline by 83% - Stock Titan
Capricor: Fourth Quarter Financial Results Overview - Bitget
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharmaletter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - Sahm
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
Capricor extends rally as FDA to review rejected cell therapy - MSN
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):